Pfizer nabs China obesity drug rights in $495 million deal

Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...
Fierce Pharma

Amid obesity push, Pfizer strikes deal worth up to $495M to market Sciwind's approved GLP-1 in China

More recently, Pfizer splashed out $150 million upfront—and put up hundreds of millions more in potential milestones—to acquire worldwide rights to a GLP-1 agonist dubbed YP05002 from Yao Pharma, a ...

U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to ...

Pfizer wins full FDA approval for Braftovi in colorectal cancer

Pfizer (PFE) stock is in focus as the FDA grants full approval for its colorectal cancer drug Braftovi, developed with Ono Pharmaceutical (OPHLF). Read more here.

Pfizer strikes $495M deal for obesity drug rights in China

Pfizer (PFE) entered a licensing agreement with China’s Sciwind Biosciences for its type 2 diabetes treatment ecnoglutide ...
Yicai Global

Pfizer Signs USD495 Million Deal for Rights to Sciwind’s Weight-Loss Drug

Ecnoglutide is one of a growing number of GLP-1 drugs in Chinese market. Sciwind gained approved for it to be used in China ...

Pfizer Secures $495 Million China Obesity Drug Deal

Pfizer (NYSE:PFE) is stepping deeper into the global weight loss race, striking a deal with Hangzhou Sciwind Bioscience for exclusive commercialization rights to ecnoglutide in mainland China, in an ...